In a bid to grow its gene therapy footprint, CSL Behring has agreed to acquire the global licensing rights to commercialise uniQure’s Phase III gene therapy programme, AMT-061 (etranacogene dezaparvovec), for the treatment of haemophilia B. The deal comes three weeks after CSL entered a strategic alliance with Seattle Children's Research Institute to develop stem cell gene therapies for primary immunodeficiency diseases.